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The PLPP3 gene encodes for a ubiquitous enzyme that dephosphorylates several lipid substrates. 
Genome-wide association studies identified PLPP3 as a gene that plays a role in coronary artery disease 
susceptibility. The aim of the study was to investigate the effect of Plpp3 deletion on atherosclerosis 
development in mice. Because the constitutive deletion of Plpp3 in mice is lethal, conditional Plpp3 
hepatocyte-specific null mice were generated by crossing floxed Plpp3 mice with animals expressing 
Cre recombinase under control of the albumin promoter. The mice were crossed onto the athero-prone 
apoE−/− background to obtain Plpp3f/fapoE−/−Alb-Cre+ and Plpp3f/fapoE−/−Alb-Cre− offspring, the 
latter of which were used as controls. The mice were fed chow or a Western diet for 32 or 12 weeks, 
respectively. On the Western diet, Alb-Cre+ mice developed more atherosclerosis than Alb-Cre− mice, 
both at the aortic sinus and aorta. Lipidomic analysis showed that hepatic Plpp3 deletion significantly 
modified the levels of several plasma lipids involved in atherosclerosis, including lactosylceramides, 
lysophosphatidic acids, and lysophosphatidylinositols. In conclusion, Plpp3 ablation in mice worsened 
atherosclerosis development. Lipidomic analysis suggested that the hepatic Plpp3 deletion may 
promote atherosclerosis by increasing plasma levels of several low-abundant pro-atherogenic lipids, 
thus providing a molecular basis for the observed results.
Lipid phosphate phosphatases (LPPs) are integral membrane proteins with six transmembrane domains, which 
display broad substrate specificity and catalyse the dephosphorylation of lipid substrates including phosphatidic 
acid, lysophosphatidic acid, ceramide 1-phosphate, sphingosine 1-phosphate and diacylglycerol pyrophosphate1. 
They belong to a larger phosphatase/phosphotransferase family that includes both membrane and soluble family 
members2.
The LPP family is composed of three enzymes in mammals: LPP1, LPP2 and LPP3, which are encoded by 
three independent genes named PLPP1, PLPP2 and PLPP3, respectively3,4. The expression of LPP2 mRNA is 
found mainly in the brain, pancreas and placenta, whereas LPP1 and LPP3 mRNA expression is ubiquitous5.
Although the three enzymes demonstrate overlapping catalytic activities and substrate preferences, selective 
targeted inactivation of the Plpp genes in mice indicates that the enzymes have non-redundant functions6. In fact, 
whereas gene inactivation of Plpp1/LPP1 or Plpp2/LPP2 does not result in any observable phenotype7,8, Plpp3/
LPP3 targeted inactivation causes profound developmental defects, thus indicating the essential role of LPP3 in 
mouse embryonic development9.
Interest in PLPP3/LPP3 has recently been raised by the results of genome-wide association studies (GWAS)10,11 
that have identified heritable single nucleotide polymorphisms in the PLPP3 gene and have suggested PLPP3 as 
a novel locus associated with coronary artery disease (CAD) susceptibility. Interestingly, the PLPP3 risk allele 
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independently predicts CAD and lacks associations with traditional risk factors such as hypertension, cholesterol, 
diabetes mellitus, obesity or smoking.
The generation of a conditional Plpp3-null allele12 has allowed for the investigation of tissue-specific deletions 
of the Plpp3 gene and their effects on vascular health. In previous studies, a lack of Plpp3 expression in smooth 
muscle cells has been reported to enhance intimal hyperplasia and vascular inflammation13, and more recently, 
the targeted inactivation of Plpp3 in endothelial and haematopoietic cells has indicated that LPP3 serves as a 
negative regulator of endothelial permeability and vascular inflammation14.
In the present study, a possible role of Plpp3 in atherosclerosis development was investigated. The target organ 
chosen for the selective inactivation of Plpp3/LPP3 was the liver, because it is one of the main organs involved 
in lipid metabolism. Hepatic Plpp3/LPP3-deficient mice were then crossed with athero-prone apolipoprotein E 
knock-out mice apoE−/−.
The results indicated that the lack of hepatic Plpp3 expression increased the levels of several pro-atherogenic 
plasma lipid species and led to accelerated atherosclerosis progression.
Results
Validation of Cre recombinase activity in the liver. To test the Cre recombinase expression specificity 
and activity, the Plpp3 locus was preliminarily examined in the genomic DNA extracted from liver and tail sam-
ples of which the latter served as a reference non-target tissue. Genomic DNA extracted from the tails of both 
Plpp3f/f apoE−/− Alb-Cre− and Plpp3f/f apoE−/− Alb-Cre+ animals showed only a PCR band corresponding to the 
floxed, unprocessed locus (Fig. 1A, lanes A-B, E-F). In contrast, the Alb-Cre transgene was active in the liver of 
Plpp3f/f apoE−/− Alb-Cre+ mice, where the processed allele was detected together with the floxed, unprocessed 
allele (Fig. 1A, lanes G-H). As expected, the Plpp3 locus was unprocessed in the liver of Plpp3f/f apoE−/− Alb-Cre− 
animals (Fig. 1A, lanes C-D).
Plpp3f/f apoE−/− Alb-Cre+ mice exhibit markedly reduced hepatic LPP3 expression, as detected 
via qPCR and Western blotting. To investigate the effect of Cre−mediated Plpp3 locus recombination 
on Plpp3 transcription, two quantitative PCR primer sets were designed, targeting the 5′ (upstream of the Cre 
recombinase mediated excision of crucial Plpp3 exons) and 3′ end (located within the DNA sequences excised 
by the Cre recombinase) of Plpp3 mRNA. This approach was able to evaluate Plpp3 promoter activity, by probing 
Plpp3 mRNA expression upstream of the site of action of Cre recombinase in the genome (5′ end primer pair) and 
the functional effect of Alb-Cre−mediated recombination, which results in truncated and non-functional Plpp3 
mRNA (3′ end primer pair).
The Cre recombinase had no effect on the 5′ end of Plpp3 mRNA in both mouse lines; both Plpp3f/f 
apoE−/− Alb-Cre− and Plpp3f/f apoE−/− Alb-Cre+ tissues showed comparable expression levels (see 
Supplementary Figure S1). In contrast, quantitative PCR using the 3′ end primer pair showed a marked decrease 
of Plpp3 mRNA expression in the livers of Plpp3f/f apoE−/− Alb-Cre+ mice compared to the livers of Plpp3f/f 
apoE−/− Alb-Cre− mice (Fig. 1B). No relevant differences were observed between the two genotypes in all the 
other tissues analysed (Fig. 1B). A major liver-specific decrease of LPP3 protein expression in Plpp3f/f apoE−/− 
Alb-Cre+ mice was also confirmed by Western blotting analysis (Fig. 1C).
Hepatic Plpp3 deletion does not affect the hepatic parenchyma and lipid deposition. The 
hepatic parenchyma was unaffected by liver-specific Plpp3 deletion; haematoxylin and eosin (H&E) staining 
showed no differences in the livers from Plpp3f/f apoE−/− Alb-Cre− and Plpp3f/f apoE−/− Alb-Cre+ mice fed chow 
diet for 32 weeks starting after weaning (8 weeks of age) (Supplementary Figure S2). The Western diet, which was 
administered for 12 weeks starting after weaning, increased lipid accumulation in both genotypes but resulted in 
no significant differences between the two mouse lines. Specifically, the percentage of Oil Red O positive area over 
the total area was 77.4 ± 2.1% in Plpp3f/f apoE−/− Alb-Cre− and 80.3 ± 5.2% in Plpp3f/f apoE−/− Alb-Cre+ mice, 
n = 10, p > 0.05 (Supplementary Figure S2). In addition, van Gieson and Periodic acid-Schiff (PAS) staining did 
not reveal any differences in collagen and glycogen deposition between Plpp3f/f apoE−/− Alb-Cre+ and Plpp3f/f 
apoE−/− Alb-Cre− mice (Supplementary Figure S2).
Plpp3f/f apoE−/− Alb-Cre+ mice on a Western diet display an enlargement of atherosclerotic 
plaques driven by an enlarged necrotic core. To investigate the role played by hepatic LPP3 during ath-
erosclerosis development, Plpp3f/f apoE−/− Alb-Cre− and Plpp3f/f apoE−/− Alb-Cre+ mice were fed, after weaning, 
a chow diet for 32 weeks or a Western diet for 12 weeks.
No differences in both plaque size and composition were observed at the aortic sinuses in the two mouse 
lines fed the chow diet (Fig. 2A,C,E and Table 1). In contrast, when challenged with a Western diet, Plpp3f/f 
apoE−/− Alb-Cre+ mice showed a 35% increase in atherosclerosis development, as compared with Plpp3f/f 
apoE−/− Alb-Cre- mice (p = 0.031) (Fig. 2B,D,F and Table 1). This increase appeared to be primarily attributable 
to a larger necrotic core area (Table 1 and Fig. 3). A trend towards increased accumulation of extracellular matrix 
(ECM) was observed in Plpp3f/f apoE−/− Alb-Cre+ mice (p = 0.063). No significant variations were found in neu-
tral lipid deposition, macrophages and smooth muscle cell accumulation (detected with Oil Red O, Mac-2 and 
α SMA staining, respectively). These variations in the plaque components resulted in a higher percentage of the 
necrotic core and a concomitantly decreased percentage of neutral lipids and macrophages (Table 1 and Fig. 3).
En-face analysis of the entire aorta of the Western diet-fed mice showed a dramatic increase in aortic athero-
sclerosis in Plpp3f/f apoE−/− Alb-Cre+ mice, specifically in the aortic arch and the thoracic segment, as compared 
with Plpp3f/f apoE−/− Alb-Cre− mice (Fig. 4A,B). No differences in atherosclerosis burden were observed in the 
abdominal aortas of either genotype (Fig. 4C).
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Figure 1. (A) Genotyping of the floxed and processed Plpp3 locus. A representative PCR screening is 
shown. Tail tips (A-B) and liver tissue (C-D) of Plpp3f/f apoE−/− Alb-Cre− mice show only the 235 bp band 
corresponding to the floxed, unprocessed Plpp3 locus. Plpp3f/f apoE−/− Alb-Cre+ mice also display the 
unprocessed Plpp3 locus band in the tail tips (E-F), but in the liver, both the unprocessed and processed allele 
(162 bp) bands are present (G-H). Liver PCR amplicons from a wild type Plpp3wt/wt mouse (I), Plpp3f/wt  
heterozygous mouse (L) and Plpp3f/f parent mouse (M) are shown as controls. Molecular weight marker, 
100 bp New England Biolabs (N); (B) Quantitative expression of the Plpp3 mRNA 3′ end. Expression levels of 
Plpp3 mRNA are shown, quantified by qPCR analysis detecting a region downstream of the Cre recombinase-
mediated floxed exons excision site. The values were normalized to the expression of the transcript in each 
corresponding tissue of the Plpp3f/f apoE−/− Alb-Cre− mice (n = 6 for liver, n = 3 for all the other tissues; 
*p = 0.0022 in Plpp3f/f apoE−/− Alb-Cre+ vs Plpp3f/f apoE−/− Alb-Cre− mouse liver by Wilcoxon rank-sum 
test). Wat = white adipose tissue; (C) Western blotting analysis of LPP3 expression. A representative image of 
the immunoblot experiments. Arrowheads indicate the presence of unglycosylated (lower band, 29 KDa) and 
glycosylated (upper bands, 33–38 KDa) forms of LPP3. The results were confirmed in three biological replicates. 
Western blotting indicated a substantial decrease in LPP3 in the livers of Plpp3f/f apoE−/− Alb-Cre+ mice 
compared with Plpp3f/f apoE−/− Alb-Cre− mice. In contrast, LPP3 levels remained unchanged in the kidney and 
brain.
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Plpp3f/f apoE−/− Alb-Cre+ mice on a Western diet exhibit increased levels of plasma triglycer-
ides. On a chow diet, Plpp3f/f apoE−/− Alb-Cre+ and Plpp3f/f apoE−/− Alb-Cre− mice did not show signifi-
cant differences in circulating total-cholesterol (TC) and HDL-cholesterol (HDL-C) levels, as well as in plasma 
triglycerides (TAG) and phospholipids (PL) (TC: 296.4 ± 47.3 vs 271.5 ± 53.1 mg/dl, respectively; HDL-C: 
Figure 2. Representative H&E photomicrographs and quantification of the maximum plaque area at 
the aortic sinuses in Plpp3f/f apoE−/− Alb-Cre+ and Plpp3f/f apoE−/− Alb-Cre− mice. The atherosclerosis 
development in the chow fed mice (n = 7–8) was comparable between the two genotypes (A,C,E). Western diet 
administration significantly worsened atherosclerosis development in Plpp3f/f apoE−/− Alb-Cre+ compared 
with Plpp3f/f apoE−/− Alb-Cre− mice (n = 16–17) (B,D,F). The data are shown as the mean ± SEM; *p = 0.031 vs 
Plpp3f/f apoE−/− Alb-Cre− by Wilcoxon rank-sum test. Bar length = 500 μ m.
www.nature.com/scientificreports/
5Scientific RepoRts | 7:44503 | DOI: 10.1038/srep44503
14.3 ± 2.7 vs 15.0 ± 4.8 mg/dl, respectively; TAG: 47.7 ± 9.6 vs 53.0 ± 13.8 mg/dl, respectively; PL: 231.1 ± 34.3 
vs 228.2 ± 46.1 mg/dl, respectively; n = 10, p > 0.05). In contrast, when the mice were administered a Western 
diet, a significant increase of TAG was observed in Plpp3f/f apoE−/− Alb-Cre+ vs Plpp3f/f apoE−/− Alb-Cre− mice 
(TAG: 301.1 ± 103.0 vs 162.4 ± 48.3 mg/dl, respectively, p = 0.0012). A trend towards an increase in plasma PL 
levels was also observed in Plpp3f/f apoE−/− Alb-Cre+ (703.9 ± 106.6 vs 588.6 ± 103.7 mg/dl, respectively, n = 10, 
p = 0.054). No significant differences were observed for TC levels (939.2 ± 190.5 vs 899.5 ± 218.8 mg/dl, respec-
tively, p > 0.05).
Hepatic Plpp3 deletion results in an increased concentration of lysophosphatidic acids, lacto-
sylceramides and several lysophospholipids in plasma. To gain insights into changes caused by Plpp3 
deletion in plasma lipid levels, lipidomic analysis was performed using global lipidomics methods as well as tar-
geted ceramide and lysophospholipid platforms. The statistical results for all lipids and comparisons together with 
q-values controlling the false discovery rate are presented in Supplementary Data S1. The Western diet, compared 
with chow diet, increased the levels of most lipid classes in both mouse lines (see Supplementary Table S1). The 
effects of hepatic Plpp3 deficiency on the plasma lipidome in mice fed chow or Western diets is shown in Tables 2 
and 3 as well as Supplementary Figure S3. The hepatic Plpp3 deletion increased the levels of lactosylceramides 
(LacCer) in mice on both the chow and Western diets. In addition, on Western diet, the levels of lysophosphatidic 
acids (LPA) and lysophosphatidylinositols (LPI) were significantly increased in Plpp3f/f apoE−/− Alb-Cre+ vs 
Plpp3f/f apoE−/− Alb-Cre− mice (Table 2). Globotriaosylceramides (Gb3) were also increased, although this vari-
ation did not reach statistical significance (p = 0.055).
Table 3 and Supplementary Figure S3 show the molecular lipids that were significantly altered by hepatic 
Plpp3 deletion in mice fed chow or a Western diet. Several LacCer lipids were significantly increased in Plpp3f/f 
apoE−/− Alb-Cre+ mice on both diets. LPAs, lysophosphatidylethanolamines (LPEs) and LPIs were also increased 
with both dietary treatments, but reached statistical significance only with the Western diet. In these lipid classes, 
the fatty acids varied from short-saturated to long-polyunsaturated fatty acids, thus indicating that the alterations 
were due to broad changes of these lipid classes rather than to alterations in individual fatty acids.
Discussion
On the basis of the results of GWAS that associated the PLPP3 gene polymorphisms with CAD susceptibility10,11, 
a possible role of Plpp3/LPP3 in atherosclerosis development was investigated in a genetically modified mouse 
model. The function of LPP3, the enzyme encoded by Plpp3, is that of dephosphorylating lipid substrates, and 
therefore, the liver was chosen as the target organ for Plpp3 deletion, because the liver is among the main sources 
of circulating plasma lipids and lipoproteins, which significantly contribute to the atherosclerosis process. It is 
well known that, during atherogenesis, LDLs enter the arterial wall, either oxidized or enzymatically degraded, 
and follow the atherogenic pathway that, through the involvement of macrophages and smooth muscle cells, leads 
to cholesterol deposition and atherosclerotic plaque formation15. Importantly, the lipoproteins responsible for 
cholesterol transport, mainly LDLs and HDLs, also contain hundreds of other associated lipid species that may 
exhibit various bioactive properties that affect the course of the disease16. Among those, LPP3 lipid substrates or 
their precursors have been identified as components of the circulating lipoproteins17.









Lesion size (μ m2) 494,884 ± 142,501 547,335 ± 150,002 355,308 ± 138,729 479,720 ± 150,857 (p = 0.031)
Necrotic core area (μ m2) 54,237 ± 23,029 51,201 ± 17,107 40,104 ± 23,571 92,879 ± 35,903 (p = 0.0001)
% total plaque area 11.3 ± 4.3 9.5 ± 2.6 11.0 ± 4.5 19.5 ± 5.1 (p = 0.0001)
Mac-2 positive area (μ m2) 92,274 ± 53,696 78,784 ± 24,882 147,094 ± 70,170 144,314 ± 49,215
% total plaque area 19.1 ± 8.0 15.8 ± 8.7 41.0 ± 10.0 31.0 ± 8.1 (p = 0.0077)
ORO-positive area (μ m2) 216,346 ± 73075 226,550 ± 59293 195,505 ± 75,335 232,692 ± 70,157
% total plaque area 44.4 ± 2.8 42.4 ± 9.1 55.9 ± 7.3 49.6 ± 9.8 (p = 0.045)
ECM-positive area (μ m2) 341,054 ± 96,641 420,028 ± 164,825 180,185 ± 71,971 254,436 ± 104,916
% total plaque area 70.3 ± 14.1 74.5 ± 15.2 50.6 ± 7.4 52.0 ± 10.4
α SMA-positive area (μ m2) 12,208 ± 4,412 9,569 ± 5,184 12,738 ± 8,922 16,419 ± 6,668
% total plaque area 2.4 ± 0.6 1.9 ± 1.3 3.4 ± 1.2 3.5 ± 1.1
CD3-positive cells (cells/100000 μ m2) 1.1 ± 0.8 0.6 ± 0.8 3.7 ± 3.4 3.4 ± 3.0
Table 1.  Plaque size and composition at the aortic sinuses of Ppap2bf/f apoE−/− Alb-Cre− and Ppap2bf/f 
apoE−/− Alb-Cre+ mice. Data are expressed as the mean ± SD; n = 7–8 in Chow diet, n = 16–17 in WD. Mac-2 
(macrophages), ORO (Oil Red O, neutral lipids), ECM (extracellular matrix), α SMA (smooth muscle cells), 
CD3 (T lymphocytes).
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Figure 3. Histological and immunohistochemical characterization of plaques at the aortic sinuses 
in Plpp3f/f apoE−/− Alb-Cre− and Plpp3f/f apoE−/− Alb-Cre+ mice fed a Western diet. Representative 
photomicrographs of the necrotic core (A,B), macrophages (Mac-2 + cells; C,D), neutral lipids (Oil Red O; 
E,F), extracellular matrix (ECM; G,H), smooth muscle cells (α SMA + celIs; I,J) and CD3 + cells (K,L). Bar 
length = 200 μ m. Asterisks mark the localization of the necrotic core (A,B).
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The liver-specific deletion of Plpp3 was achieved by crossing Plpp3-floxed mice with animals expressing Cre 
recombinase under the control of the hepatocyte-specific albumin promoter. In the livers of Plpp3f/f apoE−/− 
Alb-Cre+ mice, compared with Cre recombinase negative mice, the Plpp3 expression levels decreased over 
five-fold. The presence of a residual Plpp3 functional gene in liver, also demonstrated via PCR analysis of liver 
genomic DNA, may be explained by the presence of non-parenchymal, i.e. non-hepatocyte, cell types, such as 
sinusoidal endothelial cells, Kupffer cells, hepatic stellate cells and, often, intrahepatic lymphocytes18,19. It should 
be noted that these cells, which do not express albumin20, contribute to only 6.5% of the liver volume, but account 
for approximately 40% of the total number of liver cells19. Comparable expression levels were observed in all 
the other organs/tissues assayed in the Plpp3f/f apoE−/− Alb-Cre+ and Plpp3f/f apoE−/− Alb-Cre− animals, thus 
demonstrating the high specificity of the albumin promoter expression and Cre recombinase activity.
Figure 4. Representative photomicrographs and quantification of plaque area detected by en-face analysis 
of the aortas of mice fed a Western diet. After 12 weeks of dietary treatment, whole aortas were collected and 
en-face analysis was performed to quantify the percentage of aortic surface covered by atherosclerotic plaques. 
Atherosclerotic plaque development in the arches (A) and in the thoracic segments (B) was significantly 
increased in the aortas from Plpp3f/f apoE−/− Alb-Cre+ mice (white dots) compared with Plpp3f/f apoE−/− Alb-
Cre− mice (black dots). Atherosclerosis development at the abdominal segment (C) was not different between 
the two genotypes. Data are shown as the mean ± SEM; n = 7–8 mice per group, p = 0.0016 in the arch and 
p = 0.0016 in the thoracic segment vs Plpp3f/f apoE−/− Alb-Cre− mice by Wilcoxon rank-sum test.
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The main result of the present manuscript is the demonstration that hepatocyte-specific Plpp3 deletion is 
associated with increased atherosclerosis progression. This result was observed when mice were fed Western diet 
(+ 35% plaque area at the aortic sinus and + 86% plaque extent at the aortic arch of Alb-Cre+ vs Alb-Cre− mice), 
whereas no differences were found in atherosclerosis development between the two genotypes, when mice were 
fed a chow diet. The plaque composition was not different between the two mouse lines on a chow diet; however, 
under a Western diet, a larger necrotic core was observed in Plpp3f/f apoE−/− Alb-Cre+ mice. Interestingly, no 
differences in the main circulating plasma lipid levels were found in chow fed animals, whereas Western diet-fed 
Plpp3f/f apoE−/− Alb-Cre+ mice displayed increased TAG plasma levels vs Plpp3f/f apoE−/− Alb-Cre− mice.
Because Lpp3 is a lipid phosphatase with a large number of substrates, specific investigations into all the indi-
vidual Lpp3 targets would not be possible. Thus, with the aim of elucidating the effects of hepatic Plpp3 deletion 
on circulating lipid levels, which might affect atherosclerosis development, a lipidomic analysis was conducted 
on Plpp3f/f apoE−/− Alb-Cre− and Plpp3f/f apoE−/− Alb-Cre+ mouse plasma. Statistical analyses of the lipidomics 
data revealed that none of the lipids were significantly different after multiple hypothesis correction. However, 
significant non-adjusted p-values for several lipids in the same or related lipid classes were observed, particularly 
in mice on the Western diet. Therefore, we consider these results in mice on the Western diet to be biologically 
relevant.
Comparison of Plpp3f/f apoE−/− Alb-Cre− and Plpp3f/f apoE−/− Alb-Cre+ mice fed either a chow diet or a 
Western diet indicated a significant increase in LacCer in Plpp3f/f apoE−/− Alb-Cre+ mice. A direct link between 
LacCer accumulation and Plpp3 deletion is difficult to establish, given the complexity of the biosynthetic routes 
that convert ceramide to other bioactive sphingolipids in mammalian cells21. However, a recent study with 
apoE−/− mice, although in a different experimental setting, has reported an increase in the neutral glycosphin-
golipid LacCer when Plpp3 expression is decreased22. In animal models, increased levels of LacCer and other 
sphingolipids have been associated with the development of atherosclerosis23,24, and several enzymes in the gly-
cosphingolipid synthesis pathway have been tested as potential anti-atherosclerotic drug targets25,26. Elevated 
sphingolipid levels in human plasma have also been indicated as a risk factor for atherosclerosis development27. 
Interestingly, in a recent clinical study, different sphingolipids and glycosphingolipids, especially LacCer, have 
been associated with CAD outcome and plaque vulnerability, which was identified on the basis of an enlarged 
necrotic core28. This observation supports our results, because in Plpp3f/f apoE−/− Alb-Cre+ mice fed a Western 
diet, the worsening of atherosclerosis was associated with a larger necrotic core. In Plpp3f/f apoE−/− Alb-Cre+ 
mice fed a chow diet, however, the increase in LacCer levels was not associated with increased atherosclerosis 
development. Together, these observations do not indicate a straightforward link between higher plasma LacCer 
concentrations and atherosclerosis. However, it cannot be excluded that this plasma lipid perturbation nonethe-
less contributed to the accelerated atherosclerotic process observed in mice fed the Western diet.
Total lipids
Chow Western diet
Mean ± SEM (μmol/L) Mean relative 
difference (%) P-value
Mean ± SEM (μmol/L) Mean relative 
difference (%) P-valueAlb-Cre+ Alb-Cre− Alb-Cre+ Alb-Cre−
CE 8491 ± 486 8156 ± 509 n.s. 0.863 32812 ± 2757 28131 ± 2238 n.s 0.460
Cer d18:0 0.34 ± 0.02 0.33 ± 0.02 n.s. 0.605 2.2 ± 0.2 1.8 ± 0.1 n.s 0.173
Cer d18:1 9.9 ± 1.1 11.8 ± 1.4 n.s. 0.340 50.1 ± 3.0 50.2 ± 6.9 n.s 0.696
DAG 5.7 ± 0.4 5.9 ± 0.5 n.s. 0.779 22.4 ± 1.2 22.4 ± 2.1 n.s 1.000
Gb3 1.3 ± 0.1 1.1 ± 0.1 n.s. 0.387 4.6 ± 0.2 3.8 ± 0.3 n.s 0.055
Glc/GalCer 28.4 ± 2.3 28.3 ± 2.2 n.s. 1.000 125.3 ± 5.8 113.9 ± 4.8 n.s 0.315
LPA 0.20 ± 0.01 0.19 ± 0.01 n.s. 1.000 0.25 ± 0.02 0.20 ± 0.01 27% 0.034
LPC 582 ± 30 584 ± 18 n.s. 0.796 1113 ± 29 1059 ± 46 n.s 0.408
LPE 23.0 ± 2.1 21.1 ± 2.0 n.s. 0.436 57.2 ± 4.7 46.9 ± 3.5 n.s 0.146
LPG 9.5 ± 2.8 12.2 ± 4.1 n.s. 0.863 15.8 ± 4.4 12.9 ± 3.6 n.s 0.829
LPI 1.3 ± 0.1 1.2 ± 0.1 n.s. 0.387 3.8 ± 0.2 3.1 ± 0.2 23% 0.016
LSM 0.006 ± 0.0004 0.006 ± 0.0004 n.s. 0.436 0.014 ± 0.0015 0.012 ± 0.0012 n.s 0.829
LacCer 4.0 ± 0.3 3.0 ± 0.3 34% 0.040 21.5 ± 1.5 15.9 ± 1.6 35% 0.021
PC 1328 ± 48 1399 ± 105 n.s. 0.730 3742 ± 160 3573 ± 216 n.s 1.000
PC O 17.2 ± 1.4 14.5 ± 1.3 n.s. 0.161 61.9 ± 2.3 56.9 ± 5.2 n.s 0.360
PE O 2.3 ± 0.2 2.3 ± 0.3 n.s. 0.536 1.4 ± 0.2 1.9 ± 0.3 n.s 0.202
PI 29.0 ± 2.7 29.8 ± 2.3 n.s. 0.796 55.3 ± 2.5 52.2 ± 3.2 n.s 0.829
SM 401 ± 24 378 ± 25 n.s. 0.730 1134 ± 47 981 ± 86 n.s 0.146
Table 2.  Percentage changes in the overall amounts of lipids in classes caused by hepatic Plpp3 deletion in 
mice fed a chow or Western diet. The data are expressed as the mean ± SEM; n = 8–10, Wilcoxon rank-sum 
test. CE = Cholesteryl ester; Cer d18:0 = Ceramide d18:0; Cer d18:1 = Ceramide d18:1; DAG = Diacylglycerol; 
Gb3 = Globotriaosylceramide; Glc/GalCer = Glucosylceramide/Galactosylceramide; LPA = Lysophosphatidic 
acid; LPC = Lysophosphatidylcholine; LPE = Lysophosphatidylethanolamine; LPG = Lysophosphatidylglycerol; 
LPI = Lysophosphatidylinositol; LSM = Lysosphingomyelin; LacCer = Lactosylceramide; PC/PC 
O = Phosphatidylcholine; PE O = Phosphatidylethanolamine; PI = Phosphatidylinositol; SM = Sphingomyelin.
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The Western diet, compared with the chow diet, in both mouse lines, led to higher plasma concentrations of 
cholesteryl esters, sphingolipids and most glycerophospholipids. Interestingly, Plpp3f/f apoE−/− Alb-Cre+ mice 
showed a statistically significant increase in TAG and LPA levels vs Plpp3f/f apoE−/− Alb-Cre− mice only when 
fed the Western diet.
LPA is a well-known substrate of LPP3, which dephosphorylates and thus terminates LPA’s receptor-mediated 
signalling actions29. Previous studies have demonstrated that the liver plays a major role in LPA catabolism30. 
The increase in LPA observed in Plpp3f/f apoE−/− Alb-Cre+ mice fed a Western diet supports these observations 
and indicates the involvement of hepatic LPP3 in LPA degradation. Moreover, because LPA is an obligate inter-
mediate in TAG synthesis31, the increased LPA levels in Plpp3f/f apoE−/− Alb-Cre+ mice are consistent with the 
elevated plasma TAG levels observed. In humans, it has been observed that hyperlipidemia predisposes to the 
generation of LPA in the circulation32, and higher concentrations of serum LPA have been associated with the 
occurrence of acute coronary syndromes33. Moreover, in apoE−/− mice, systemic treatment with unsaturated LPA 
has been shown to have pro-inflammatory and pro-atherosclerotic effects34. In our study, we observed increased 
circulating amounts of LPA 18:1 in the sn-2 position and 20:4 in the sn-1 position. These LPA molecular species 
have previously been recognized to have high atherogenic and thrombogenic potency in the lipid-rich cores 
of human atherosclerotic plaques35 as well as to promote dyslipidemia36. Interestingly, an association between 
necrotic core formation and LPA accumulation has been highlighted in previous studies35. These findings support 
a link between the elevated plasma LPA concentration and the increased necrotic core areas observed in the aortic 
sinus of Plpp3f/f apoE−/− Alb-Cre+ mice fed a Western diet.
The Plpp3f/f apoE−/− Alb-Cre+ mice fed a Western diet also displayed a significant increase of LPI plasma con-
centration compared with that in Western-fed Plpp3f/f apoE−/− Alb-Cre− mice. LPI is synthesized by several cell 
types37–39 and is generated by phospholipase A2, which catalyses the hydrolysis of phosphatidylinositol and gen-
erates LPI and free arachidonic acid40. Most of the biological effects of LPI are mediated by the receptor GPR5541. 
LPI may play a pro-atherogenic role by promoting endothelial dysfunction. Indeed, several studies have indicated 
that LPI negatively regulates endothelial cells migration and induces VCAM-1 and ICAM-1 expression42,43.
Finally, Gb3 showed a trend towards increased levels in Plpp3f/f apoE−/− Alb-Cre+ mice fed a Western diet. 
This increase is consistent with the observed elevation of LacCer, because Gb3 is synthesized from LacCer by α 
1,4-galactosyltransferase44. Circulating Gb3 is transported in LDL and HDL particles45,46. In the arterial wall, 
Gb3 accumulation leads to extracellular matrix deposition and calcification in the media47, whereas, within the 
endothelium, it promotes the production of reactive oxygen species, upregulates the expression of adhesion mol-
ecules48, and causes endothelial dysfunction49.
In conclusion, the present work provides the first demonstration of the role of Plpp3/LPP3 in atherosclero-
sis development in an animal model and further provides experimental evidence supporting clinical observa-
tions relating PLPP3 polymorphisms to CAD susceptibility. Additionally, plasma lipidomic analysis suggested a 
Lipid
Chow Western diet
Mean ± SEM (μmol/L) Mean relative 
difference (%) P-value
Mean ± SEM (μmol/L) Mean relative 
difference (%) P-valueclass name Alb-Cre+ Alb-Cre− Alb-Cre+ Alb-Cre−
LPA LPA 0:0/18:1 0.006 ± 0.0005 0.005 ± 0.0007 n.s 0.505 0.012 ± 0.0012 0.007 ± 0.0006 66% 0.009
LPA LPA 20:4/0:0 0.019 ± 0.002 0.015 ± 0.002 n.s 0.190 0.035 ± 0.003 0.026 ± 0.002 31% 0.016
LPC LPC 0:0/18:2 10.0 ± 0.8 11.0 ± 0.3 −9% 0.040 5.1 ± 0.3 4.7 ± 0.3 n.s. 0.408
LPE LPE 18:0 4.3 ± 0.3 3.2 ± 0.3 36% 0.027 9.5 ± 0.9 8.6 ± 1.0 n.s. 0.633
LPE LPE 20:3/0:0 0.12 ± 0.02 0.16 ± 0.03 n.s 0.605 0.77 ± 0.14 0.47 ± 0.05 64% 0.043
LPE LPE 20:4/0:0 0.59 ± 0.07 0.50 ± 0.09 n.s 0.387 2.19 ± 0.35 1.32 ± 0.14 66% 0.009
LPE LPE 22:6/0:0 0.73 ± 0.10 0.79 ± 0.18 n.s 0.863 1.95 ± 0.18 1.43 ± 0.07 36% 0.016
LPG LPG 18:1/0:0 0.008 ± 0.001 0.009 ± 0.001 n.s 1.000 0.065 ± 0.004 0.052 ± 0.002 24% 0.012
LPI LPI 18:1/0:0 0.025 ± 0.002 0.021 ± 0.002 n.s 0.436 0.400 ± 0.032 0.278 ± 0.012 44% 0.001
LPI LPI 18:2/0:0 0.064 ± 0.006 0.049 ± 0.002 30% 0.024 0.093 ± 0.009 0.072 ± 0.003 n.s. 0.068
LPI LPI 22:5/0:0 0.007 ± 0.001 0.006 ± 0.001 n.s 0.200 0.033 ± 0.003 0.025 ± 0.002 32% 0.034
LPI LPI 22:6/0:0 0.019 ± 0.002 0.017 ± 0.001 n.s 0.666 0.071 ± 0.006 0.054 ± 0.005 31% 0.043
LacCer LacCer d18:1/16:0 1.11 ± 0.11 0.80 ± 0.07 38% 0.031 6.01 ± 0.39 4.6 ± 0.4 31% 0.043
LacCer LacCer d18:1/22:0 0.62 ± 0.04 0.52 ± 0.05 n.s 0.113 2.96 ± 0.18 2.28 ± 0.25 29% 0.027
LacCer LacCer d18:1/24:0 0.43 ± 0.04 0.35 ± 0.03 n.s 0.222 3.22 ± 0.25 2.31 ± 0.30 39% 0.034
LacCer LacCer d18:1/24:1 1.37 ± 0.12 0.97 ± 0.10 42% 0.031 6.65 ± 0.57 4.64 ± 0.57 44% 0.034
PC O PC P-18:0/20:4 (PC O-18:1/20:4) 2.26 ± 0.16 1.57 ± 0.12 44% 0.002 6.21 ± 0.35 5.38 ± 0.56 n.s. 0.173
SM SM 42:2 95.4 ± 4.7 91.5 ± 4.3 n.s 0.863 231.9 ± 9 195.4 ± 12.5 19% 0.027
Table 3.  Percentage changes in the amounts of lipid species caused by hepatic Plpp3 deletion in mice 
fed a chow or Western diet. Data are expressed as mean ± SEM; n = 8–10, Wilcoxon rank-sum test. 
LPA = Lysophosphatidic acid; LPC = Lysophosphatidylcholine; LPE = Lysophosphatidylethanolamine; 
LPG = Lysophosphatidylglycerol; LPI = Lysophosphatidylinositol; LacCer = Lactosylceramide; PC 
O = Phosphatidylcholine; SM = Sphingomyelin.
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molecular basis for the observed results, indicating low-abundant lipid species as potential players in the devel-
opment of atherosclerosis associated with Plpp3 hepatic deficiency.
Methods
Procedures involving animals and their care were conducted in accordance with institutional guidelines that are 
in compliance with national (D.L. No. 26, March 4, 2014, G.U. No. 61 March 14, 2014) and international laws and 
policies (EEC Council Directive 2010/63, September 22, 2010: Guide for the Care and Use of Laboratory Animals, 
United States National Research Council, 2011). The experimental protocol was approved by the Italian Ministry 
of Health (Protocollo 2012/4 and 434/2016-PR).
Mouse models. Conditional Plpp3/LPP3 liver-specific null mice were generated by crossing mice with the 
Plpp3/LPP3 gene flanked by loxP sites (Plpp3f/f), which were kindly provided by Dr. Susan R. Schwab12, with 
mice expressing the Cre recombinase under control of a hepatocyte-specific albumin promoter (Alb-Cre+, The 
Jackson Laboratory, USA). Two oligonucleotides (Cre_a: 5′ -AGGTGTAGAGAAGGCACTCAGC-3′ , Cre_b: 5′ - 
CTAATCGCCATCTTCCAGCAGG-3′ ) were used to screen wild-type (no PCR amplicon) and Cre recombinase 
positive mice (412 bp). The PCR cycling conditions were 95 °C for 4 min, followed by 40 cycles of 30 s at 95 °C, 
30 s at 60 °C and 30 s at 72 °C. Three oligonucleotides (fwd_a: 5′ -CTACAGATGTCAGTCAGTGTG-3′ , fwd_c: 
5′ -GAAGTGCCATTACTCTCTCAGC-3′ and rev_d: 5′ -CCAGGGTGCTATCTATCTGTAAC-3′ ) were used to 
screen for wild-type, floxed and recombined Plpp3 alleles in the genomic DNA (191 bp, 235 bp and 162 bp, respec-
tively), as described elsewhere12.
Plpp3f/f mice, hemizygous for Cre recombinase, were crossed onto an athero-prone genetic background 
through multiple crosses with homozygous apolipoprotein E knock-out (apoE−/−) mice (Charles River 
Laboratories, Italy) to obtain Plpp3f/f apoE−/− Alb-Cre+ (lacking Plpp3 hepatic expression) and Plpp3f/f apoE−/− 
Alb-Cre− (as control) mice. A set of three primers (eko_a: 5′ -GCCTAGCCGAGGGAGAGCCG-3′ , eko_b: 
5′ -TGTGACTTGGGAGCTCTGCAGC-3′ and eko_c: 5′ -GCCGCCCCGACTGCATCT-3′ ) was used to screen 
wild type, apoE−/− and apoE+/− mice, as described elsewhere (http://jaxmice.jax.org/strain/002052.html).
All mice were maintained on a C57Bl/6 background. Plpp3f/f apoE−/− Alb-Cre− and Plpp3f/f apoE−/− Alb-Cre+ 
mice, at 8 weeks of age, were divided into two groups and fed a Western diet (TD.88137, Harlan Laboratories, 
Italy) for 12 weeks or a regular chow diet (4RF21, Mucedola, Italy) for 32 weeks.
Plasma and tissue harvesting. At the end of the experimental period, after an overnight fast, blood 
was collected from the retro-orbital plexus, under 2% isoflurane anaesthesia (Forane, Abbot Laboratories Ltd, 
Illinois, USA), into tubes containing 0.1% (w/v) EDTA and plasma was separated after centrifugation for 10 min 
at 5900× g at 4 °C. The mice were then sacrificed under general anaesthesia with 2% isoflurane and the blood was 
removed by perfusion with phosphate-buffered saline (PBS). The aorta was rapidly dissected from the aortic root 
to the iliac bifurcation, and as much periadventitial fat and connective tissue were removed as much as possible. 
The aorta was then longitudinally opened, pinned flat on a black wax surface in ice-cold PBS and photographed 
unstained50,51 for plaque quantification (see En face analysis). For histological/immunohistochemical analysis, 
the hearts were removed, fixed in 10% formalin for 30 min and transferred into PBS containing 20% sucrose 
(w/v) overnight at 4 °C before being embedded in OCT compound (Sakura Finetek, The Netherlands) and stored 
at − 80 °C.
The apex of the heart, liver, stomach, duodenum, jejunum, ileum, large intestine, kidney, brain, abdominal 
white adipose tissue, lung, inguinal lymph node, spleen, testis and ovary were immediately snap-frozen in liquid 
nitrogen for subsequent analyses.
Quantitative PCR. Total RNA was isolated using a NucleoSpin RNA extraction kit (Macherey–Nagel, 
Germany) and total RNA (1 μ g) was reverse transcribed with random hexamers and MultiScribe reverse tran-
scriptase (Applied Biosystems, California, USA) by following the manufacturer’s instructions.
The expression level of the 5′  end (5p_fw: 5′  -ACCGTCGAGGGTTTTACTGC-3′  ;  5p_rev : 
5′ -GAGCGGGACTTCTCCTTGAG-3′ ) and 3′ end (3p_fw: 5′ -CACGGGATTGTCACGGGTAT-3′ ; 5p_rev: 
5′ -AGGTCGGACACGAAGAACAC-3′ ) of the murine Plpp3 gene was quantified by qPCR on a Biorad CFX 
Connect thermal cycler with iQ SYBR Green Supermix (Biorad, California, USA) in 15 μ l reactions, with 300 μ 
M of each primer. The cycling conditions were 95 °C for 4 min, followed by 40 cycles of 30 s at 95 °C, 30 s at 
55 °C and 30 s at 72 °C. A final melting curve analysis assured the authenticity of the target product. The 
housekeeping gene cyclophilin A (Ppia) (ppia_fw: 5′ -AGCACTGGGGAGAAAGGATT-3′ ; ppia_rev: 5′ 
-AGCCACTCAGTCTTGGCAGT-3′ ) was used for normalization.
Western blotting analysis. Liver, kidney and brain tissue samples were lysed in ice-cold RIPA buffer 
(50 mM Tris–Cl pH 8.0, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulphate) 
supplemented with a 2× Protease Inhibitor Cocktail (Sigma-Aldrich). The lysates were then sonicated and the 
protein concentration was determined using the BCA protein assay method. A total of 60 μ g of proteins was sep-
arated by SDS–PAGE in 10% acrylamide gels and transferred to a membrane. The following antibodies were used 
for Western blotting analysis: a previously validated purified rabbit anti-LPP3 (1:2000, Sigma, custom-made52,53) 
generated against a peptide antigen spanning the residues 2–7 of human LPP1 and a beta actin monoclonal 
mouse antibody (clone AC-15, Sigma-Aldrich). The membranes were then washed and further incubated with 
horseradish peroxidase-conjugated anti-rabbit or anti-mouse IgG (#7074 and #7076 respectively, Cell Signaling, 
Maryland, USA). The signal was detected with the Pierce ECL Western Blotting Substrate (Thermo Scientific, 
Massachusetts, USA) and quantified with Image Studio 5.2.5 (Li-Cor, Nebraska, USA).
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Histology. Aortic sinus. Serial cryosections (7 micron thick) of the aortic sinus were cut. Approximately 25 
slides with 3 cryosections/slide were obtained, spanning the three cusps of the aortic valves. Every sixth slide was 
stained with haematoxylin and eosin (H&E, Bio-Optica, Italy) to determine the plaque area, which was calculated 
as the mean area of those sections showing the three cusps of the aortic valves and the necrotic core area, which 
was defined as the acellular area that was not stained by H&E54. The adjacent slides were stained with Oil Red O 
(Sigma-Aldrich, Missouri, USA) to detect intraplaque neutral lipids and with Masson’s trichrome (Bio-Optica, 
Milano, Italy) to determine extracellular matrix deposition. Macrophages, smooth muscle cells (SMCs) 
and T lymphocytes were detected using an anti-Mac2 antibody (CL8942, Cedarlane, Ontario, Canada), an 
anti-α -smooth muscle actin antibody (Ab5694, Abcam, Cambridge, UK) and an anti-CD3 antibody (MAB4841, 
R&D Systems, Minnesota, USA), respectively. Detection was performed using an ImmPRESS reagent kit (Vector 
Laboratories, Peterborough, UK). 3,3′ -Diaminobenzidine was used as the chromogen (Sigma-Aldrich), and the 
sections were counterstained with Gill’s haematoxylin (Bio-Optica). The Aperio ScanScope GL Slide Scanner 
(Aperio Technologies, California, USA) was used to acquire digital images that were subsequently processed with 
the ImageScope software. An operator blinded to the dietary treatment and genotype quantified plaque size and 
composition.
Liver. The left lobes were isolated, immersion-fixed in 10% formalin for 24 hours, dehydrated in a graded scale 
of ethanol, and paraffin embedded. Serial sections (4 micron thick) were cut and stained with H&E. In addition, 
Periodic acid-Schiff (PAS) staining was performed to evaluate glycogenosis and van Gieson staining was per-
formed to evaluate collagen deposition. Another lobe of the liver was also embedded in OCT and cryosections 
(7 micron thick) were stained with Oil Red O to detect neutral lipid accumulation. Hepatic lipid deposition was 
measured as the percentage of Oil Red O positive area over the total area measured by the ImageScope software.
En Face Analysis. The images of the aorta were recorded with a stereomicroscope-dedicated camera (IC80 
HD, MZ6 microscope, Leica Microsystems, Germany) and analysed using the ImageJ image processing program 
(http://rsb.info.nih.gov/ij/). An operator blinded to the dietary treatment quantified the atherosclerotic plaques.
Lipid analysis. Plasma TC, TAG and PL were measured with enzymatic methods (ABX Diagnostics, France 
and B.L. Chimica, Italy). HDL-C levels were measured after the precipitation of apoB-containing lipoproteins 
with PEG (20% w/v) in 0.2 mol/L glycine (pH 10)55.
Lipidomic analyses. Ceramides and glycerophospholipids were extracted using a modified Folch lipid 
extraction method56, and lysophospholipids were extracted with the butanol extraction method57, using a 
Hamilton Microlab Star robot (Hamilton Robotics, Switzerland). The samples were spiked with known amounts 
of non-endogenous synthetic internal standards. After lipid extraction, the samples were reconstituted in chloro-
form:methanol (1:2, v/v) and synthetic external standards were spiked into the extracts post-extraction. The 
extracts were stored at − 20 °C before MS analysis.
In Shotgun Lipidomics, the lipid extracts were analysed using a hybrid triple quadrupole/linear ion trap mass 
spectrometer (QTRAP 5500, SCIEX, Canada) equipped with a robotic nanoflow ion source (TriVersa NanoMate, 
NY, USA) according to the methods described by Ståhlman and colleagues58. The molecular lipids were analysed 
in both positive and negative modes by using Multiple Precursor Ion Scanning (MPIS) based methods59,60. The 
molecular lipid species were identified and quantified in semi-absolute or absolute amounts58. Targeted molecular 
lipids were analysed on a hybrid triple quadrupole/linear ion trap mass spectrometer (QTRAP 5500) equipped 
with an ultra-high pressure liquid chromatography (UHPLC) system (Eksigent ekspert 100-XL, SCIEX, Canada) 
using multiple reaction monitoring (MRM)–based methods in positive and negative ion modes. Regioisomers 
1-acyl-2-LPL (sn1) and 2-acyl-1-LPL (sn2) were detected on the basis of their different elution times. The lipids 
were normalized to their respective internal standard and to the sample amounts. All the lipidomics data are 
provided as μ mol/L in Supplementary Data S2. The raw mass spectrometric data files are available upon request 
for non-commercial scientific purposes.
Statistical analyses. Statistical analyses for the lipidomics data were performed using R (Version x64 3.3.2). 
Wilcoxon rank-sum tests were performed to compare the differences between the study groups. In comparisons, 
the mean relative differences are presented as relative percentage differences in the mean concentrations of the 
groups. The results of all statistical analyses for the lipids are presented in Supplementary Data S1, which also 
shows Q-values which indicate false discovery rate.
Statistical analyses for all other comparisons were performed using the GraphPad Prism version 7.0b for Mac, 
GraphPad Software, La Jolla California USA, www.graphpad.com and the group differences were tested for sta-
tistical significance with Wilcoxon rank-sum test. In the statistical analyses, p < 0.05 was considered significantly 
different.
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